Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip Podcasts

Listen to Scrip podcasts for our perspectives on biopharma R&D, deal-making, product strategies and other key commercial topics.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.

A Deep Dive Into The Game-Changing Drugs For Skin Diseases

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

Ocugen CEO Musunuri On Gene Therapy Candidates, The Omicron Advantage

Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Pfizer buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; Lilly looks to volume-driven growth; and Novavax talks about diversity in clinical trials.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: alarms sound over Omicron; Sanofi boosts vaccine pipeline via acquisition; J&J’s immunology plans; Chinese firms step onto world stage; and top execs share insights to shape India’s R&D push.

APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

See All

ABOUT

Informa Pharma Intelligence podcasts discuss key ideas and insights affecting biopharma and medtech, brought to you by our global team of editors. Listen on-demand to our perspectives on the latest industry developments.

FIND ALL PHARMA INTELLIGENCE PODCASTS ON:

MORE PODCASTS

UsernamePublicRestriction

Register